Prodotti competitors / Area Oncology
Ribociclib - Findings from the MAINTAIN study
![Immagine News](/media/l4el5htd/cat-2.jpg?anchor=center&mode=crop&width=722&height=442)
Significant PFS Benefit in Patients with HR-positive, HER2-negative MBC Who Switched Endocrine Treatment and Received Ribociclib After Previous CDK4/6 Inhibitor and Different Endocrine Therapy
the full article is availabel at ESMO Oncology News (Link)
Grazie per il tuo feedback!